Department of Anesthesiology, Pain Mechanisms Laboratory, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, United States.
Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, United States.
Front Public Health. 2022 Jun 17;10:893009. doi: 10.3389/fpubh.2022.893009. eCollection 2022.
The U.S. legal cannabis market is saturated with products containing high levels of tetrahydrocannabinol (THC), with no distinction between medical and recreational programs. This omnipresence of potent cannabis products seems to be driven by the recreational realm, where cannabis with the highest THC content is prized. This prevalence of highly potent cannabis is conveyed to medical programs, which places consumers (patients) at higher risk for over consumption and cannabis use disorder. Thus, understanding what factors influence the market that patients face in medical cannabis programs could shed light on the risks of legal cannabis. The supply and demand dynamic of the US for-profit cannabis market could explain the current market composition; therefore, we postulate that a financial gain could influence the perpetuation of the prevalence of high THC products in legal cannabis dispensaries. We investigate whether THC content in popular cannabis products correlates with higher prices and assess whether some attributes (type of product, chemovars, or presence of cannabidiol (CBD) affect the association of THC with price.
We focus on the world's largest cannabis market, California. We randomly selected dispensaries across the state, screened for a web presence and product menu, determined the most prevalent product type, and collected THC and CBD concentration, price, and other product attributes.
We observed that herbal products were more common, they had THC concentrations greater than 10%, and THC concentrations positively correlated with price. This correlation existed in flower and preroll presentations, all chemovar, and independently of the level of CBD. CBD did not correlate with price; however, the presence of CBD diminished the THC and price correlation particularly in products with high THC (>15%).
Overall, highly potent herbal cannabis products (>15% THC) are the majority of products offered and more expensive regardless of product type or chemovar in California dispensaries, suggesting that a financial gain contributes to the current market composition. Efforts to limit the availability of highly potent THC products and educate consumers about potential harms are needed.
美国合法大麻市场充斥着高含量四氢大麻酚(THC)的产品,没有区分医用和娱乐用项目。这种无处不在的强效大麻产品似乎是由娱乐领域推动的,在那里,THC 含量最高的大麻最受欢迎。这种高含量大麻的普及也传递到了医用项目中,这使得消费者(患者)面临过度消费和大麻使用障碍的风险更高。因此,了解影响医用大麻项目中患者面临的市场的因素,可以揭示合法大麻的风险。美国盈利性大麻市场的供需动态可以解释当前的市场构成;因此,我们假设经济利益可能会影响高 THC 产品在合法大麻药房中的持续存在。我们调查了流行大麻产品中的 THC 含量是否与较高的价格相关,并评估了某些属性(产品类型、化学变种或是否存在大麻二酚(CBD))是否会影响 THC 与价格的关联。
我们专注于世界上最大的大麻市场——加利福尼亚州。我们随机选择了全州的药房,筛选出有网络存在和产品菜单的药房,确定了最常见的产品类型,并收集了 THC 和 CBD 浓度、价格和其他产品属性。
我们观察到草药产品更为常见,其 THC 浓度超过 10%,并且 THC 浓度与价格呈正相关。这种相关性存在于花和 preroll 产品中,所有化学变种,并且独立于 CBD 水平。CBD 与价格不相关;然而,CBD 的存在特别是在高 THC(>15%)产品中,降低了 THC 和价格的相关性。
总体而言,高含量的草药大麻产品(>15% THC)是加利福尼亚州药房提供的大多数产品,无论产品类型或化学变种如何,价格都更高,这表明经济利益有助于当前的市场构成。需要努力限制高含量 THC 产品的供应,并向消费者宣传潜在的危害。